virginie Firlej

Dr. virginie Firlej

UR TRePCa, Paris-Est Créteil University, Paris, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2019 in Nature
Verified
Journal Article
Closed access
PDF file
PMPhilippe Mauffrey
Philippe Mauffrey
NTNicolas Tchitchek
Nicolas Tchitchek
VBVilma Barroca
Vilma Barroca
ABAlexis-Pierre Bemelmans
Alexis-Pierre Bemelmans
virginie Firlejvirginie Firlej
virginie Firlej
CMClaire Magnon
Claire Magnon

31 January 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
MMMichaël Monet
Michaël Monet
V'yacheslav LEHEN'KYIV'yacheslav LEHEN'KYI
V'yacheslav LEHEN'KYI
FGFlorian Gackiere
Florian Gackiere
virginie Firlejvirginie Firlej
virginie Firlej
MVMatthieu Vandenberghe
Matthieu Vandenberghe
Natalia PrevarskayaNatalia Prevarskaya
Natalia Prevarskaya
Castration resistance in prostate cancer (PCa) constitutes an advanced, aggressive disease with poor prognosis, associated with uncontrolled cell proliferation, resistance to apoptosis, and enhanced invasive potential. The molecular mechanisms involved in the transition of PCa to castration resistance are obscure. Here, we report that the nonselective cationic channel transient receptor potential vanilloid 2 (TRPV2) is a distinctive feature of castration-resistant PCa. TRPV2 transcript levels were higher in patients with metastatic cancer (stage M1) compared with primary solid tumors (stages T2a and T2b). Previous studies of the TRPV2 channel indicated that it is primarily involved in cancer cell migration and not in cell growth. Introducing TRPV2 into androgen-dependent LNCaP cells enhanced cell migration along with expression of invasion markers matrix metalloproteinase (MMP) 9 and cathepsin B. Consistent with the likelihood that TRPV2 may affect cancer cell aggressiveness by influencing basal intracellular calcium levels, small interfering RNA–mediated silencing of TRPV2 reduced the growth and invasive properties of PC3 prostate tumors established in nude mice xenografts, and diminished expression of invasive enzymes MMP2, MMP9, and cathepsin B. Our findings establish a role for TRPV2 in PCa progression to the aggressive castration-resistant stage, prompting evaluation of TRPV2 as a potential prognostic marker and therapeutic target in the setting of advanced PCa. Cancer Res; 70(3); 1225–35

18 February 2009 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
CDCéline Delloye-Bourgeois
Céline Delloye-Bourgeois
EBElisabeth Brambilla
Elisabeth Brambilla
MCMarie-May Coissieux
Marie-May Coissieux
CGCéline Guenebeaud
Céline Guenebeaud
RPRémy Pedeux
Rémy Pedeux
ABAgnès Bernet
Agnès Bernet
Netrin-1 may promote colorectal and breast tumorigenesis, by inhibiting apoptosis induced by its dependence receptors, deleted in colorectal cancer (DCC) and uncoordinated-5-homolog (UNC5H). The status of netrin-1 and its receptors in non–small cell lung cancer (NSCLC) was unknown. The levels of netrin-1 and its receptors were analyzed in a panel of 92 NSCLC and 25 human lung cancer cell lines by quantitative reverse transcription–polymerase chain reaction and immunohistochemistry. In lung cancer cell lines that express netrin-1, the expression of netrin-1 was inhibited by using small interfering RNA (siRNA), or interference with netrin-1 was performed by treatment with a decoy recombinant DCC ectodomain protein (DCC-5Fbn). Cell death was monitored with a trypan blue exclusion assay or by measuring caspase-3 activity. The effect of netrin-1 interference on tumor growth was analyzed by DCC-5Fbn intratumoral or netrin-1 siRNA intraperitoneal injection in mice engrafted with lung cancer cell lines. All statistical tests were two-sided. High levels of netrin-1 were found in 43 of the 92 NSCLC tumor samples (47%). Interference with netrin-1 in human lung cancer cell lines was associated with UNC5H-mediated cell death in vitro (percentage of cell death in untreated and in DCC-5Fbn–treated cells = 8% and 26%, respectively, difference = 18%, 95% confidence interval [CI] = 10% to 26%; P = .049) and with lung tumor growth inhibition and/or regression in xenografted nude mice (12 mice in DCC-5Fbn–treated group and 13 mice in control group). Mean volume of control and DCC-5Fbn–treated tumors on day 46 was 489 and 84 mm 3 , respectively (difference = 404 mm 3 , 95% CI = 145 to 664 mm 3 ; P < .001). Almost half of the NSCLC tissue samples examined expressed high levels of netrin-1. Extracellular targeting of the interaction between netrin-1 and UNC5H may be a promising therapeutic approach for NSCLCs that express netrin-1.

15 December 2011 in Cancer Research
Verified
Journal Article
Closed access
PDF file
virginie Firlejvirginie Firlej
virginie Firlej
JMJacques R.R. Mathieu
Jacques R.R. Mathieu
CGCristèle Gilbert
Cristèle Gilbert
Loic LemonnierLoic Lemonnier
Loic Lemonnier
JNJessica Nakhlé
Jessica Nakhlé
FCFlorence Cabon
Florence Cabon
The antitumor effects of pharmacologic inhibitors of angiogenesis are hampered in patients by the rapid development of tumor resistance, notably through increased invasiveness and accelerated metastasis. Here, we reevaluated the role of the endogenous antiangiogenic thrombospondin 1 (TSP1) in prostate carcinomas in which angiogenesis is an active process. In xenografted tumors, we observed that TSP1 altogether inhibited angiogenesis and fostered tumor development. Our results show that TSP1 is a potent stimulator of prostate tumor cell migration. This effect required CD36, which also mediates TSP1 antiangiogenic activity, and was mimicked by an antiangiogenic TSP1-derived peptide. As suspected for pharmacologic inhibitors of angiogenesis, the TSP1 capacities to increase hypoxia and to trigger cell migration are thus inherently linked. Importantly, although antiangiogenic TSP1 increases hypoxia in vivo, our data show that, in turn, hypoxia induced TSP1, thus generating a vicious circle in prostate tumors. In radical prostatectomy specimens, we found TSP1 expression significantly associated with invasive tumors and with tumors which eventually recurred. TSP1 may thus help select patients at risk of prostate-specific antigen relapse. Together, the data suggest that intratumor disruption of the hypoxic cycle through TSP1 silencing will limit tumor invasion. Cancer Res; 71(24); 7649–58. ©2011 AACR.

1 August 2006 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
YLYvan Paul de Launoit
Yvan Paul de Launoit
JBJean-Luc Baert
Jean-Luc Baert
ACAnne Chotteau-Lelievre
Anne Chotteau-Lelievre
DMDidier Monte
Didier Monte
LCLaurent Coutte
Laurent Coutte
KVKathye Verreman
Kathye Verreman

1 July 2013 in Neoplasia
Verified
Journal Article
Open access
PDF file
Stéphane TERRYStéphane TERRY
Stéphane TERRY
PMPascale Maillé
Pascale Maillé
HBHabiba Baaddi
Habiba Baaddi
LKLaurence Kheuang
Laurence Kheuang
PSPascale Soyeux
Pascale Soyeux
FVFrancis Vacherot
Francis Vacherot
Neoplasia publishes the results of novel investigations in all areas of oncology research.